Skip to main navigation Skip to search Skip to main content

Survival after combined modality therapy for pancreatic cancer

  • Howard W. Bruckner
  • , Shalom Kalnicki
  • , Jack Dalton
  • , Harry Snady
  • , Gary K. Schwartz
  • , Margaret R. Chesser
  • , Deborah Lehrer
  • , John Mandeli
  • , Noam Harpaz
  • , Cynthia Janus

Research output: Contribution to journal › Article › peer-review

Abstract

Twenty consecutive patients with unresectable, locally advanced pancreatic cancer were treated with split courses of radiotherapy (RT) and simultaneous multidrug chemotherapy consisting of 5 fluorouracil, continuous infusion, streptozotocin, and cisplatin. A separate, retrospective study identified a group of 28 contemporary patients with less advanced pancreatic cancers, all of which were successfully resected. The survival rate of the two groups were similar over the first 2 years, although it initially favored the unresectable group. This pattern of survival among patients treated with combined modality therapy provides a basis for new studies. At the two clinical extremes, these include treatment of unrespectable tumors previously considered ineligible for this treatment and initial treatment before resection of stage I tumors.

Original languageEnglish (US)
Pages (from-to)199-203
Number of pages5
JournalJournal of clinical gastroenterology
Volume16
Issue number3
DOIs
StatePublished - Apr 1993
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • 5-Fluorouracil
  • Chemotherapy
  • Cisplatin
  • Combined modality therapy
  • Pancreatic cancer
  • Radiotherapy
  • Streptozotocin

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Survival after combined modality therapy for pancreatic cancer'. Together they form a unique fingerprint.

Cite this